These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

970 related articles for article (PubMed ID: 29741648)

  • 41. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brain volume loss in multiple sclerosis is independent of disease activity and might be prevented by early disease-modifying therapy.
    Slezáková D; Kadlic P; Jezberová M; Boleková V; Valkovič P; Minar M
    Neurol Neurochir Pol; 2023; 57(3):282-288. PubMed ID: 37144903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
    van de Pavert SH; Muhlert N; Sethi V; Wheeler-Kingshott CA; Ridgway GR; Geurts JJ; Ron M; Yousry TA; Thompson AJ; Miller DH; Chard DT; Ciccarelli O
    J Neurol Neurosurg Psychiatry; 2016 May; 87(5):461-7. PubMed ID: 25926483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
    Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis.
    Brass SD; Benedict RH; Weinstock-Guttman B; Munschauer F; Bakshi R
    Mult Scler; 2006 Aug; 12(4):437-44. PubMed ID: 16900757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
    Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
    JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
    Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
    Nourbakhsh B; Azevedo C; Maghzi AH; Spain R; Pelletier D; Waubant E
    J Neurol Sci; 2016 Jul; 366():229-233. PubMed ID: 27288812
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.
    Pontillo G; Cocozza S; Lanzillo R; Russo C; Stasi MD; Paolella C; Vola EA; Criscuolo C; Borrelli P; Palma G; Tedeschi E; Morra VB; Elefante A; Brunetti A
    AJNR Am J Neuroradiol; 2019 Jan; 40(1):99-106. PubMed ID: 30573464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls.
    Elkady AM; Cobzas D; Sun H; Seres P; Blevins G; Wilman AH
    Mult Scler Relat Disord; 2019 Aug; 33():107-115. PubMed ID: 31181540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.
    Kearney H; Rocca MA; Valsasina P; Balk L; Sastre-Garriga J; Reinhardt J; Ruggieri S; Rovira A; Stippich C; Kappos L; Sprenger T; Tortorella P; Rovaris M; Gasperini C; Montalban X; Geurts JJ; Polman CH; Barkhof F; Filippi M; Altmann DR; Ciccarelli O; Miller DH; Chard DT
    Mult Scler; 2014 Jan; 20(1):72-80. PubMed ID: 23812283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis.
    Papadopoulos K; Tozer DJ; Fisniku L; Altmann DR; Davies G; Rashid W; Thompson AJ; Miller DH; Chard DT
    Mult Scler; 2010 Apr; 16(4):427-33. PubMed ID: 20086026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis.
    Aladro Y; López-Alvarez L; Sánchez-Reyes JM; Hernández-Tamames JA; Melero H; Rubio-Fernández S; Thuissard I; Cerezo-García M
    J Neurol; 2018 Oct; 265(10):2182-2189. PubMed ID: 29995292
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability.
    Kerbrat A; Gros C; Badji A; Bannier E; Galassi F; Combès B; Chouteau R; Labauge P; Ayrignac X; Carra-Dalliere C; Maranzano J; Granberg T; Ouellette R; Stawiarz L; Hillert J; Talbott J; Tachibana Y; Hori M; Kamiya K; Chougar L; Lefeuvre J; Reich DS; Nair G; Valsasina P; Rocca MA; Filippi M; Chu R; Bakshi R; Callot V; Pelletier J; Audoin B; Maarouf A; Collongues N; De Seze J; Edan G; Cohen-Adad J
    Brain; 2020 Jul; 143(7):2089-2105. PubMed ID: 32572488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain atrophy in clinically early relapsing-remitting multiple sclerosis.
    Chard DT; Griffin CM; Parker GJ; Kapoor R; Thompson AJ; Miller DH
    Brain; 2002 Feb; 125(Pt 2):327-37. PubMed ID: 11844733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patterns of cortical grey matter thickness reduction in multiple sclerosis.
    Fujimori J; Fujihara K; Wattjes M; Nakashima I
    Brain Behav; 2021 Apr; 11(4):e02050. PubMed ID: 33506628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability.
    Carotenuto A; Cacciaguerra L; Pagani E; Preziosa P; Filippi M; Rocca MA
    Brain; 2022 Aug; 145(8):2785-2795. PubMed ID: 34919648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.